Targovax Revenue and Competitors

Claim your profile

Oslo, Norway

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Targovax's estimated annual revenue is currently $6.8M per year.(i)
  • Targovax's estimated revenue per employee is $155,000

Employee Data

  • Targovax has 44 Employees.(i)
  • Targovax grew their employee count by 16% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$13.5M8730%N/AN/A
#2
$2.6M17-45%N/AN/A
#3
$2.6M176%N/AN/A
#4
$9.1M599%N/AN/A
#5
$3.7M249%N/AN/A
#6
$6.8M4416%N/AN/A
#7
$11.8M7627%N/AN/A

Activating the Patient's Immune System to Fight Cancer Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine. Targovax's lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It is used as a therapeutic cancer vaccine, and has a proven ability to activate the immune system and generate tumor-specific immune responses. In phase I trials, ONCOS-102 has demonstrated innate and adaptive immune activation, both locally and systemically, which has been associated with clinical benefit. ONCOS-102's lead indication is mesothelioma, where the virus is currently being tested in a randomized phase Ib/II trial. Another trial, in advanced melanoma, is expected to produce important proof of concept data for checkpoint inhibitor refractory patients within the next 6-12 months. Targovax is also developing a neo-antigen cancer vaccine targeting tumors that express mutated forms of RAS. The TG vaccine program has shown a signal of efficacy in a 32-patient trial with TG01 in resected pancreatic cancer. A next generation product candidate, TG02 is currently being combined with Keytruda® (pembrolizumab) in a phase Ib trial in colorectal cancer. Both the ONCOS and TG programs are protected by a portfolio of IP and know-how, and have the potential to generate multiple product candidates.

keywords:N/A

N/A

Total Funding

44

Number of Employees

$6.8M

Revenue (est)

16%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Targovax News

2022-04-17 - Targovax ASA: Issuance of restricted stock units (RSUs) to the board members

Reference is made to the annual general meeting of Targovax ASA (the "Company") on 20 April 2022 (the "AGM") where election of members to...

2022-04-17 - Targovax ASA announces the appointment of two new Board Directors

Oslo, Norway , 21 April 2022 - Targovax ASA (OSE: TRVX) announces that the. General Meeting has elected Dr Raphael Clynes and Mr Thomas...

2022-04-17 - Targovax ASA: Minutes from the Annual General Meeting

2022 Targovax ASA AGM minutes.pdf. ***. For further information, please contact: Erik Digman Wiklund , CEO Phone: +47 413 33 536

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M445%N/A
#2
$5.1M445%N/A
#3
$5.2M4644%N/A
#4
$7.5M4612%N/A
#5
$5.3M465%N/A